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lated outcomes. Clinical data was collected from EURTAC and JMDB clinical trials,
which compared erlotinib and pemetrexed/ cisplatin, respectively, with different
doublet chemotherapy regimens. Assumptions were used to allow this indirect
comparison, namely, pemetrexed/ cisplatin relative efficacy observed in JMDB ad-
enocarcinoma patients also applies to patients with EGFR mutations and that
different doublet chemotherapy regimens used in the mentioned trials are of
equivalent efficacy. RESULTS: The HR for disease progression of erlotinib versus
pemetrexed/ cisplatin, in patients with mNSCLC and EGFR mutations was 0.41
(95% CI: 0.27–0.62, p 0.001). This is equivalent to a 59% reduction in the risk of
disease progression. CONCLUSIONS: Despite some limitations and uncertainties
associated with indirect comparisons, erlotinib presents itself as a significantly
more effective first-line treatment for mNSCLC patients with EGFR mutations,
showing a significant disease progression risk reduction when compared to pem-
etrexed/ cisplatin.
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OBJECTIVES: This study explores and describes real therapeutic features (preva-
lence, incidence, length of therapy, prescriptions, etc.), treatment effectiveness in
therapy groups and management costs of MRCC patients treated with M-TOR ki-
nase inhibitors. METHODS: The analysis used patients’ data from the National
Health Insurance Fund Administration (NHIFA). Subjects were patients with a di-
agnosis of MRCC (with ICD-10 code C64) (14.794 such patients exist), who filled a
renal cancer drug prescription between Jan 2008 and July 2011 (1.648 patients).
Descriptive methods and Kaplan-Meier analysis for survival and progression free
survival were applied. An assumption was made that progression free survival can
be described by therapy persistence due to the features of treatment lines.
RESULTS: Patients usually filled for first line therapy (mainly sunitinib) with a dose
for a two-month long and second line therapy (mainly sorafenib) with a dose for
one-month long period at one time. Number of sunitinib patients grew significantly
during the analysis period mainly due to new patients. A huge proportion of pa-
tients discontinued the therapy within three months, which shows a high ratio of
non-responsive patients. Comparison of different therapies, examination of pro-
gression free survival curves, showed that first line therapies (sunitinib) have lon-
ger persistence than second line therapies (sorafenib). Therapy persistence was
generally shorter than the period in which patients were on therapy based on filling
of therapies. Progression free survival was longer in case of patients who were on a
therapy for at least 11 months. Difference between therapies in ordinary survival
couldn’t be showed due to the short period of analysis.CONCLUSIONS:Main part of
patients is non-responsive to MRCC therapies in Hungary. We found that there is a
difference between MRCC therapies in progression free survival of MRCC patients.
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OBJECTIVES: The benefits of inhaled corticosteroids (ICS)in patients with asthma
or chronic obstructive pulmonary disease (COPD) are based mainly on their anti-
inflammatory effects. Chronic inflammation has been implicated in the pathogen-
esis of several cancers, including lung cancer and laryngeal cancer. The aim of this
study was to elucidate the association between ICS use and diagnosis of lung
cancer and laryngeal cancer. METHODS: A nested case–control study was con-
ducted based on the Korean national claims database. The eligible cohort consisted
of 792,687 new adult users of inhaled respiratory medications between January1,
2007, and December31, 2010. Patients diagnosed with lung cancer or laryngeal
cancer after initiation of inhaled medication were identified as cases. For each case
individual, up to five control individuals matched for age, sex, diagnosis of asthma
or COPD, Charlson Comorbidity Index scores, number of health care visits, and
initiation date were selected. RESULTS: From the cohort population, 9,177 individ-
uals diagnosed with lung cancer were matched with 37,048 controls. Additionally,
408 individuals with laryngeal cancer and 1,651 controls were matched. ICS use
was associated with a decreased rate of lung cancer diagnosis [adjusted odds ratio
(aOR), 0.79; 95% confidence interval (CI), 0.69–0.90]. Furthermore, the association
between ICS use and decreased risk of lung cancer was dose dependent (P0.0001
for the trend). However, no reduction in the risk of laryngeal cancer among ICS
users was identified (aOR, 1.06; 95% CI, 0.62–1.18). CONCLUSIONS: The use of ICS is
associated with a reduced risk of lung cancer but not of laryngeal cancer.
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OBJECTIVES: To characterize treatment modalities and health outcomes in indi-
viduals treated for unresectable stage III or stage IV melanoma and to compare
these outcomes across patients in the public and private health care systems in
Brasil, respectively. METHODS: This is a multicentre retrospective chart review,
characterizing treatment patterns and clinical outcomes among individuals with
unresectable stage III or stage IV melanoma diagnosed or relapsed between January
1, 2008 and December 31, 2009. All patients had at least two months follow up in 12
private and public centers, divided in South, South-East and North-East regions in
Brazil. Overall survival from time of diagnosis was characterized using a Kaplan-
Meier analysis. Key results are reported stratified by public and private health
systems. RESULTS: Treatment was received by 161 of 165 eligible patients (63 pri-
vate and 98 public). The majority of patients received systemic therapy (76.4%) and
surgery (57.8%). Radiotherapy was received by 37.9% and 9.3% received supportive
care rather than another line of therapy. A larger proportion of private patients
received systemic therapy compared to public patients (92.1% versus 66.3%), spe-
cifically chemotherapy and immunotherapy. Second-line therapy was adminis-
tered to 65% vs. 26.5% of private and public patients respectively. Complete or
partial response was observed in 16.1% of overall first-line patients (22% in private
patients, 11.3% in public patients). Median survival was 14.4 months (95% CI, 10.6-
21.6); 11.5 months for public patients and 19.2 months for private patients (p0.07).
CONCLUSIONS: Overall results demonstrate the lack of effective treatment for
advanced melanoma. Patients treated at private centres received more treatment
and also had a difference in the median survival when compared with those
treated at the public health care. This finding should be better studied in future
research.
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OBJECTIVES: To perform a systematic review and meta-analysis of all randomized
controlled trials comparing the efficacy of Sipuleucel-T versus placebo for asymp-
tomatic or minimally symptomatic metastatic castration-refractory prostate can-
cer (mCRPC). METHODS: Several databases were searched, including MEDLINE,
EMBASE, LILACS, and CENTRAL. The endpoints were overall survival (OS), time to
progression (TTP) and side effects. We performed a meta-analysis (MA) of the pub-
lished data. The results are expressed as Hazard Ratio (HR) or Risk Ratio (RR), with
their corresponding 95% confidence intervals (CI95%). RESULTS: The final analysis
included 3 trials comprising 737 patients. The TTP was similar in patients who
received Sipuleucel-T or placebo (fixed effect: HR0.89; CI95%0.75 to 1.05;
p0.16), with no heterogeneity detected on this analysis (Chi2  2.14, df  2
(P0.34); I2  6%). The results showed a higher overall survival in patients treated
with Sipuleucel-T (fixed effect: HR0.74; CI95%0.61 to 0.89; p0.001; NNT 3). We
found no heterogeneity on this analysis either (Chi2 1.46, df 2 (P0.48); I2 0%).
The incidence of adverse events (grade  3) was the same in both groups.
CONCLUSIONS: Sipuleucel-T prolongs overall survival in patients with asymptom-
atic or minimally symptomatic mCRPC.
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OBJECTIVES: In Germany, not only academic and non-academic hospitals but also
office-based practitioners play an important role in providing care to cancer pa-
tients. Bone metastases (BM) are a late-stage complication of several cancer types
for which the current gold standard treatment are bisphosphonates. Aim of this
study was to investigate the initiation of cancer related bisphosphonate therapy
depending on the type of treatment facility. METHODS: This retrospective cohort
study is based on a purchasable oncology database (IMS®Oncology Analyzer). This
database provides comprehensive insight into cancer patient care with backdata
until 1999. The analysed time period was January 2003 to December 2011. Main
outcome measure was the initiation of bisphosphonate therapy depending on the
type of treatment facility. A multivariate logistic regression model was fitted with
the bisphosphonate therapy as dependent variable and indicator variables for of-
fice-based practitioners, general hospital and academic hospital. Demographic and
clinical data were also analysed and included as confounders. RESULTS: Patients
with BM following breast cancer (BC) (n1957, mean age: 63.9 years), prostate can-
cer (PC) (n1425, mean age: 70.8), non-small-cell-lung cancer (NSCLC) (1,543 pa-
tients, mean age: 63.6) or multiple myeloma (MM) (1,079 patients, mean age: 67.7)
were selected. Of them 1338 (68.3%) of BC, 843 (59.2%) of PC, 795 (51.5%) of NSCLC
and 912 (84.5%) of MM patients received treatment with bisphosphonates. MM
patients have significant higher chances to receive bisphosphonate therapy in
academic hospitals compared to office based practitioners (HR 1.64, p0.01). In PC
and BC, no differences between treatment facilities were found. For NSCLC patients
the chance of bisphosphonate treatment was lower in academic hospital than at
office-based practitioners (HR: 0.59, p0.04). CONCLUSIONS: Factors influencing
the therapy initiation with bisphosphonates have to be identified in order to ensure
optimal treatment of BM. Cancer type may play a role as shown in this study.
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